Techstars Partners With Alphabit Fund and Launchpool to Launch New Blockchain-Focused Accelerator in London
30.6.2021 14:00:00 EEST | Business Wire | Press release
Techstars, the worldwide network that helps entrepreneurs succeed, today announced an exciting new accelerator program. The Launchpool Web3 Techstars Accelerator focuses on working with entrepreneurs to build blockchain technology and tokenisation protocols to drive towards the decentralised future of finance.
The program runs in partnership with Alphabit Fund, the first regulated cryptocurrency and digital asset investment fund, and Launchpool, a regulatory compliant investment platform that offers private seed guaranteed investment opportunities to 35,000 members in its community.
Techstars maintains notable experience and expertise in the blockchain space, with a number of strong blockchain companies in the Techstars portfolio including Chainalysis, recently valued at $2 billion, Arweave, TradingView, and more.
“Blockchain technology has the potential to shift the control of monetary value and information and disrupt global business processes, as the Internet did in the early 2000s,” said Techstars General Manager Gagan Bhatia. “Working with Alphabit and the Launchpool community to support leading companies in this space is an incredible opportunity and an investment in the decentralized economy of the future.”
Located in London, the Launchpool Web3 Techstars Accelerator will work with ten startups each year over an intensive, three-month acceleration period. They will receive funding, hands-on mentorship, exposure to a minimum viable community, access to curated workshops and resources, and join the Techstars global network for life. Applications open from September 13 to December 1, 2021 and the first year of the accelerator will operate from March to June 2022.
“Alphabit is thrilled Techstars is partnering with Launchpool and us to bring the first Techstars accelerator to the crypto world. As firm believers in a multichain future, and being passionate about mainstream adoption, this first of its kind accelerator is proud to be chain agnostic,” said Shane McQuillan, VP Strategy of Alphabit.
Learn about Launchpool Web3 Techstars Accelerator here. For partnership opportunities with Techstars, contact Will Robinson or visit techstars.com/corporations.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas — entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,500 companies with a combined market cap of more than $200B. www.techstars.com
About Alphabit
One of the first regulated crypto asset funds, Alphabit has forged a reputation for investing in companies at the cutting edge of the blockchain revolution. Alphabit believes, supports, and invests in the decentralised economy of the future, with a generous portfolio of startups, protocols, and DeFi solutions that address an alternative to traditional financial systems. www.alphabit.fund
About Launchpool
Launchpool is a regulatory compliant initiative started in 2020 by Alphabit Digital Currency Fund with the aim of providing fair guaranteed access to early stages of project raises to the retail community. With the ethos of ‘Egalitarian Investment’, Launchpool’s global community of 35,000 investors believe in the idea of being your own VC, while supporting the startups ecosystem with a minimum viable community, resources, access to funding opportunities, and enabling partnerships across the blockchain ecosystem. www.launchpool.xyz
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210630005495/en/
Contact information
Media Contacts
Ali Whitman
Techstars
ali.whitman@techstars.com
Roxana Nasoi
Launchpool
roxana@launchpool.xyz
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom